Vopratelimab clinical trials
Also written JTX-2011.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses vopratelimab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Jounce Therapeutics, Inc. (4)
Often tested with
Tested in the same studies.
Pimivalimab (1)
Studies
Open first, then newest update. How each study uses vopratelimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsTerminatedPhase 1/2Jounce Therapeutics, Inc.NCT04319224Written as VopratelimabReport a problem
- Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing RegimenTerminatedPhase 2Jounce Therapeutics, Inc.NCT04549025Added to pimivalimab in lung cancer cohortsWritten as VopratelimabReport a problem
- JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsCompletedPhase 1/2Jounce Therapeutics, Inc.NCT02904226Written as JTX-2011Report a problem
- Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerCompletedPhase 2Jounce Therapeutics, Inc.NCT03989362Written as VopratelimabReport a problem
Tested with established drugs · 3 — they are given beside it
- Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid TumorsTerminatedPhase 1/2Jounce Therapeutics, Inc.NCT04319224Written as VopratelimabReport a problem
- JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsCompletedPhase 1/2Jounce Therapeutics, Inc.NCT02904226Written as JTX-2011Report a problem
- Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerCompletedPhase 2Jounce Therapeutics, Inc.NCT03989362Written as VopratelimabReport a problem
Tested in a combination · 1 — another drug in the study is under test too
- Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing RegimenTerminatedPhase 2Jounce Therapeutics, Inc.NCT04549025Added to pimivalimab in lung cancer cohortsWritten as VopratelimabReport a problem
Codes
What other systems call vopratelimab · ClinicalTrials.gg INT017726
- UNII (FDA) QXN20J93AHVOPRATELIMABOne source FDA
- NCI Thesaurus C129876VopratelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QXN20J93AH | VOPRATELIMAB | One source FDA |
| NCI Thesaurus | C129876 | Vopratelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.